The honest verdict up front: Combined HRT — estrogen plus a progestogen, prescribed to women who still have a uterus — is associated with a small increase in breast cancer risk that grows with duration of use. Estrogen-only HRT, used by women without a uterus, is associated with little or no increase, and in the largest randomized trial women on estrogen alone had a slightly lower breast cancer rate than those on placebo. The excess risk from combined HRT is measured in a handful of extra cases per 1,000 women over years of use — an increase broadly similar to being overweight after menopause, and one input into a personal decision, not a veto. This article explains the numbers; it is not medical advice for you specifically.
Why the fear is so much bigger than the number
In July 2002 the Women's Health Initiative (WHI) combined-HRT trial was stopped early, and headlines announced a "26% increase" in breast cancer. That relative figure is real, but it was reported almost entirely without the context that makes a number usable. A 26% rise on top of a small baseline is still a small number. In the WHI, the actual excess worked out to roughly 8 extra invasive breast cancers per 10,000 women each year of use.1
Two further problems compounded the misread. The WHI enrolled women whose average age was 63 — well past menopause — yet the results were generalized to 50-year-olds starting HRT for hot flushes. And the trial used one specific combination (oral conjugated equine estrogen plus medroxyprogesterone acetate, an older synthetic progestin) that is not what most women are prescribed today. Age at starting matters in its own right: this is what researchers call the timing hypothesis (or "window of opportunity") — the overall balance of benefits and risks appears more favourable when HRT is begun near the onset of menopause, generally before age 60 or within about 10 years of the last period, than when it is started many years later.6 The consequence of the 2002 overreaction was a generation of women who stopped or never started HRT, many of whom endured avoidable symptoms and lost the bone and possibly cardiovascular benefits of treatment near menopause. Correcting that overcorrection is the whole point of framing the risk honestly.
The crucial distinction: combined vs estrogen-only
The most under-known fact in this entire topic is that the two main types of HRT behave very differently for breast tissue.
Estrogen-only HRT is prescribed to women who have had a hysterectomy (no uterus, so no need for a progestogen to protect the womb lining). In the WHI estrogen-alone trial of women with hysterectomy, conjugated estrogen was associated with a statistically significant ~23% reduction in invasive breast cancer and in breast cancer death over long-term follow-up.2 Large observational data find at most a very small increase. The honest bottom line: estrogen alone carries little or no meaningful breast cancer increase.
Combined HRT (estrogen plus a progestogen) is what drives the signal. The progestogen component appears to be the main contributor to the increased risk, which is why the estrogen-only picture is so much more reassuring. For the difference between these regimens, see our explainer on estrogen-only vs combined HRT.
The numbers in absolute terms
The most authoritative modern estimate comes from a 2019 individual-participant meta-analysis of over 100,000 women published in The Lancet. For women of average weight starting HRT at age 50 and using it for 5 years, the extra breast cancers diagnosed across ages 50–69 were about:3
- Estrogen only: ~1 extra case per 200 users
- Estrogen + intermittent progestogen: ~1 extra per 70 users
- Estrogen + daily progestogen: ~1 extra per 50 users
The baseline for context: about 63 in every 1,000 never-users (6.3%) would be diagnosed with breast cancer over that window anyway. The excess rises with longer use, and some of it persists for more than a decade after stopping — though it does decline over time. Here is how the combined-HRT figure sits alongside everyday exposures nobody panics about:
| Factor | Approx. extra cases per 1,000 women | Notes |
|---|---|---|
| Estrogen-only HRT (5 yrs) | ~0 to 5 (WHI trial: slightly fewer) | Little or no meaningful increase |
| Combined HRT, daily progestogen (5 yrs) | ~20 | Rises with duration; declines after stopping |
| Being overweight/obese after menopause | ~24 | Cancer Research UK estimate |
| Drinking ~2 units of alcohol a day | ~5 | Risk climbs with each extra daily unit |
| Never using HRT (reference) | ~63 baseline cases | The background rate for all women |
Read honestly, combined daily HRT for 5 years adds roughly what carrying extra weight after menopause adds, and more than a couple of daily drinks. None of these are reasons to dismiss the risk — but they show it is an ordinary, manageable risk, not a catastrophe. The point of absolute framing is not to make HRT sound risk-free; it is to make the risk the right size in your mind.
Does the type of progestogen matter?
Possibly. Several studies suggest that micronized progesterone (body-identical, e.g. the ingredient in oral progesterone capsules) may carry a lower breast signal than older synthetic progestins — one systematic review put the relative risk at about 0.67 compared with synthetic progestins.4 Importantly, this reassurance is strongest for the first ~5 years of use, because that is how long most of the studies followed women. The evidence is still evolving, so this is a "may be lower," not a "proven safe." It is a reasonable thing to ask your prescriber about — not a reason to self-select a product.
The route of delivery matters mainly for a different risk. Transdermal HRT — patches and gels — is not associated with the increased blood-clot (venous thromboembolism, or VTE) risk seen with oral estrogen, because it bypasses first-pass metabolism in the liver; oral estrogen carries the higher clot risk. That transdermal-vs-oral distinction is about clot risk, not breast cancer: the breast signal is driven by the progestogen component, not by whether the estrogen is a pill, patch, or gel. See how HRT delivery methods compare for the full picture.
What happens to the risk after you stop?
The excess risk falls after stopping HRT, but not instantly. The 2019 Lancet analysis found some elevated risk persisted for more than 10 years after cessation, with the amount depending on how long HRT was used.3 The WHI similarly showed the combined-HRT signal diminishing over time off treatment. In plain terms: stopping helps, gradually — and short-term use around the menopause transition carries less cumulative risk than many years of use.
Where the risk calculus changes
These population averages are not your personal number. The math shifts if you have a strong family history of breast cancer, a known BRCA mutation, a personal history of breast cancer, or dense breast tissue flagged on screening. For women who have had breast cancer, HRT is generally avoided. Your baseline weight, alcohol intake, and age at starting all move the figure too. This is exactly why breast cancer risk is one input a clinician weighs against your symptoms and your bone, heart, and quality-of-life picture — not a single yes/no switch. It is also worth knowing that in 2025 the FDA removed the boxed warning from menopause hormone therapy products, reflecting this more nuanced modern reading of the evidence — see what the boxed-warning removal means.
When to talk to your clinician
Book a conversation with your prescriber — do not start, stop, or change HRT on your own — if any of the following apply:
- You are considering HRT and want your personal risk estimated, factoring in family history and other risk factors.
- You have a family history of breast or ovarian cancer, a BRCA mutation, or a personal history of breast cancer.
- You have been on combined HRT for several years and want to review whether to continue, switch regimens, or step down.
- You notice a new breast lump, skin or nipple change, or breast pain that is new or one-sided.
- You have any unexplained vaginal bleeding on HRT or after menopause — this always needs prompt evaluation and should never be assumed to be a side effect. See postmenopausal bleeding and bleeding on HRT.
Keep up with routine mammographic screening whether or not you take HRT. To make the appointment productive, our list of questions to ask your doctor about HRT covers exactly what to raise, and the menopause symptom score helps you show your clinician how much your symptoms are actually affecting you — the other side of the risk-benefit scale. For the wider picture, start with our menopause hub.
This article is educational and is not a substitute for advice from your own clinician, who can weigh your individual history. It does not recommend starting, stopping, or changing any medication or dose.
